Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432
AI Summary:
The study reports promising efficacy and safety of olaparib plus durvalumab in women with germline BRCA1/2 mutations (gBRCAm) and platinum-sensitive relapsed ovarian cancer (PSROC). The combination also showed encouraging clinical activity in women with non-gBRCAm PSROC. No new safety signals were identified.AI Topics:
Purpose: Early results from the phase II MEDIOLA study (NCT02734004) in germline BRCA1- and/or BRCA2-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSROC) showed promising efficacy and safety with olaparib plus durvalumab. We report efficacy and safety of olaparib plus durvalumab in an expansion cohort of women with gBRCAm PSROC (gBRCAm expansion doublet cohort) and two cohorts with non-gBRCAm PSROC, one of which also received bevacizumab (non-gBRCAm doublet and triplet cohorts).
Patients and Methods: In this open-label, multicenter study, PARP inhibitor-naïve patients received olaparib plus durvalumab treatment until disease progression; the non-gBRCAm triplet cohort also received bevacizumab. Primary endpoints were objective response rate (ORR; gBRCAm expansion doublet cohort), disease control rate (DCR) at 24 weeks (non-gBRCAm cohorts), and safety (all cohorts).
Results: The full analysis and safety analysis sets comprised 51, 32, and 31 patients in the gBRCAm expansion doublet, non-gBRCAm doublet, and non-gBRCAm triplet cohorts, respectively. ORR was 92.2% [95% confidence interval (CI), 81.1–97.8] in the gBRCAm expansion doublet cohort (primary endpoint); DCR at 24 weeks was 28.1% (90% CI, 15.5–43.9) in the non-gBRCAm doublet cohort (primary endpoint) and 74.2% (90% CI, 58.2–86.5) in the non-gBRCAm triplet cohort (primary endpoint). Grade ≥ 3 adverse events were reported in 47.1%, 65.6%, and 61.3% of patients in the gBRCAm expansion doublet, non-gBRCAm doublet, and non-gBRCAm triplet cohorts, respectively, most commonly anemia.
Conclusions: Olaparib plus durvalumab continued to show notable clinical activity in women with gBRCAm PSROC. Olaparib plus durvalumab with bevacizumab demonstrated encouraging clinical activity in women with non-gBRCAm PSROC. No new safety signals were identified.
Drew, Yvette
Author
Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432
See full publications listKim, Jae-Weon
Author
Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432
See full publications listPenson, Richard T.
Author
Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432
See full publications listO'Malley, David M.
Author
Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432
See full publications listParkinson, Christine
Author
Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432
See full publications listRoxburgh, Patricia
Author
Krebs, Matthew G. and Forster, Martin and Majem, Margarita and Peguero, Julio and Iams, Wade and Clay, Tim and Roxburgh, Patricia and Doger, Bernard and Bajaj, Pawan and Barba, Andres and Perera, Suvini and Mueller, Christian and Triebel, Frédéric (2024) Eftilagimod alpha (a soluble LAG-3 protein) combined with pembrolizumab in second-line metastatic NSCLC refractory to anti–programmed cell death protein 1/programmed death-ligand 1-based therapy: final results from a phase 2 study. JTO Clinical and Research Reports, 5 (11): 100725. ISSN 2666-3643
Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432
See full publications listPlummer, Ruth
Author
Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432
See full publications listIm, Seock-Ah
Author
Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432
See full publications listImbimbo, Martina
Author
Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432
See full publications listFerguson, Michelle
Author
Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432
See full publications listRosengarten, Ora
Author
Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432
See full publications listSteeghs, Neeltje
Author
Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432
See full publications listKim, Min Hwan
Author
Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432
See full publications listGal-Yam, Einav
Author
Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432
See full publications listTsoref, Daliah
Author
Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432
See full publications listKim, Jae-Hoon
Author
Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432
See full publications listYou, Benoit
Author
Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432
See full publications listDe Jonge, Maja
Author
Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432
See full publications listLalisang, Roy
Author
Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432
See full publications listGort, Eelke
Author
Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432
See full publications listBastian, Sara
Author
Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432
See full publications listMeyer, Kassondra
Author
Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432
See full publications listFeeney, Laura
Author
Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432
See full publications listBaker, Nigel
Author
Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432
See full publications listAh-See, Mei-Lin
Author
Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432
See full publications listDomchek, Susan M.
Author
Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432
See full publications listBanerjee, Susana
Author
Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432
See full publications listAvailable under License Creative Commons Attribution Non-commercial No Derivatives.
Download (531kB) | Preview
